FY2025 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure (NASDAQ:QURE) – Investment analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of uniQure in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will earn ($2.93) per share for the year, up from their prior estimate of ($2.99). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s Q4 2025 earnings at ($0.81) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at $7.95 EPS, FY2028 earnings at $18.09 EPS and FY2029 earnings at $19.96 EPS.

Other research analysts have also issued reports about the company. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Leerink Partners increased their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Mizuho increased their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Finally, Guggenheim reiterated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $12.51 on Friday. The business has a fifty day simple moving average of $14.59 and a 200 day simple moving average of $9.92. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $609.77 million, a price-to-earnings ratio of -2.52 and a beta of 0.38. uniQure has a one year low of $3.73 and a one year high of $19.18.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 26,727 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the transaction, the chief executive officer now owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. The trade was a 4.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the completion of the transaction, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. The trade was a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 96,044 shares of company stock worth $1,001,040 in the last ninety days. 4.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently made changes to their positions in the business. RTW Investments LP bought a new stake in shares of uniQure during the 3rd quarter valued at about $49,000. Atria Investments Inc bought a new stake in shares of uniQure during the 3rd quarter valued at about $53,000. Quarry LP bought a new position in uniQure in the third quarter worth approximately $58,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in uniQure in the third quarter worth approximately $69,000. Finally, Twin Tree Management LP bought a new position in uniQure in the fourth quarter worth approximately $77,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.